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Abstract
Background: Axial spondyloarthritis (axSpA) is characterized by significant bone loss caused by dysregulation of
physiological bone turnover, possibly resulting from intensified differentiation of osteoclasts. The aim of this study
was to reevaluate the levels of osteoclastogenesis-mediating factors: soluble RANKL, M-CSF, OPG and other
cytokines in sera of untreated, with sDMARDs and/or bDMARDs, axSpA patients and to test whether these sera
influence differentiation of healthy monocytes towards osteoclast lineage.
Methods: Bone remodeling molecules (RANKL, M-CSF, OPG, IL-6, OSM, IL-17A, TGFβ, and TNFα) were evaluated in
27 patients with axSpA and 23 age and sex-matched controls. Disease activity (BASDAI, ASDAS) and inflammatory
markers (ESR, CRP) were assessed. Monocytes obtained from healthy individuals were cultured in vitro in presence
of sera from 11 randomly chosen axSpA patients and 10 controls, with addition of exogenous M-CSF and/or RANKL
or without. Osteoclastic differentiation was assessed analyzing osteoclast markers (cathepsin K and RANK at mRNA
level) and with osteoclast-specific staining.
Results: axSpA patients’ sera levels of soluble RANKL were significantly lower and M-CSF, IL-6, OSM, IL-17A and
TNFα significantly higher in comparison to controls, whereas of OPG and TGFβ were comparable in both groups.
Numbers of generated in vitro osteoclasts and cathepsin K mRNA levels did not differ between cultures
supplemented with sera of healthy and axSpA patients, both in the absence and presence of M-CSF. Instead,
addition of exogenous RANKL boosted osteoclastogenesis, which was significantly higher in cultures with axSpA
sera. Furthermore, sera from axSpA patients induced substantially higher levels of RANK mRNA, independently of M-
CSF and RANKL stimulation.
Conclusion: We show that, paradoxically, serum levels of soluble RANKL observed in axSpA are in fact significantly
lower in comparison to healthy blood donors. Our results indicate that sera of axSpA patients - in contrary to
healthy subjects - contain circulating, soluble factors (presumably IL-6, OSM, IL-17A, TNFα and others) able to
stimulate healthy monocytes responsiveness to even relative low RANKL serum levels, by inducing high
RANK mRNA expression and - as a net effect - boosting their osteoclastogenic potential. We suggest also that
locally produced RANKL in axSpA may induce overactive osteoclasts from their precursors.
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Key messages:
1) In comparison to healthy subjects, lower serum
level of free soluble RANKL is observed in axSpA
patients.
2) Sera from axSpA patients influence in vitro
osteoclastogenesis by up-regulation of RANK mRNA
in healthy monocytes.
Background
Human receptor activator of nuclear factor–κB ligand
(RANKL) and monocyte colony-stimulating factor
(M-CSF) are two key molecules for osteoclast formation
from peripheral blood monocytes and their activation,
whereas osteoprotegerin (OPG) acts as a decoy receptor
for the RANKL [1]. These cytokines play critical role in
physiological bone turnover and their dysregulation leads
to impairment of osteoclasts generation and excessive
bone formation, as observed in numerous rheumatic dis-
eases including spondyloarthritis (SpA). Abnormal serum
levels of M-CSF and RANKL may thus represent a crucial
factor in SpA pathology. There is however substantial dis-
crepancy regarding serum RANKL levels in SpA patients
(especially axSpA). Previous studies reported either higher
or unchanged serum RANKL levels in axial spondyloar-
thritis (axSpA) patients in comparison to healthy subjects
[2–5]. Therefore, in this study we especially aimed to re-
evaluate the levels of key osteoclastogenesis mediators –
soluble RANKL and M-CSF - in sera of axSpA patients.
Osteoclastogenesis is also induced by several other cyto-
kines, including tumor necrosis factor alpha (TNFα),
Interleukin 6 (IL-6), IL-17A, or transforming growth fac-
tor β (TGFβ) [6–9]. The role of RANKL-independent
(non-canonical) pathways of osteoclast formation and ac-
tivation seems to be especially important in inflammatory
rheumatic diseases such as axSpA, rather than in physio-
logical bone resorption or postmenopausal osteoporosis
[6]. Moreover, as demonstrated recently, in ankylosing
spondylitis (AS), osteoclast precursors (monocytes) show
impaired osteoclasts characteristic gene expression profile
[5]. It is unclear, whether this is a result of aberrant extra-
cellular stimulation of monocytes circulating in axSpA pa-
tients’ body fluids, their inherited trait, or both.
Considering the potential important role of non-canonical
osteoclastogenesis in SpA pathophysiology we evaluated
levels of several additional cytokines (namely IL-6,
Oncostatin M (OSM), IL-17A, TGFβ, and TNFα) in
sera of studied groups. Consequently, by utilising
in-vitro differentiation system, we examined whether
these sera (being a natural milieu of monocytes) influ-
ence healthy monocyte differentiation towards osteo-
clasts, to avoid potential interference with inherited
disregulation of physiological monocyte functions in
axSpA patients. For that, in serum-driven differentiated
cells we determined the gene expression of osteoclast
markers such as cathepsin K and RANK as well as per-
formed osteoclast-specific cell staining. Our results indicate
that RANKL-independent, serum soluble factors-mediated
osteoclastogenesis may indeed play a significant role in
axSpA bone remodeling by substantially influencing ex-
pression of RANK mRNA in healthy osteoclast precursors.
Patients and methods
Patients and controls
Twenty-seven patients with axSpA (18 AS, 9 nr-axSpA)
according to the Assessment of SpondyloArthritis Inter-
national Society (ASAS) classification criteria and 23
healthy age and sex-matched controls were enrolled in
this study [10]. Patients were under 45 years, with rela-
tively recent disease onset (not exceeding 10 years of
symptoms duration), naïve to synthetic and/or biological
Disease Modifying Anti-Rheumatic Drugs (sDMARDs,
bDMARDs) and without the administration of systemic
glucocorticosteroids. Patients provided a signed in-
formed consent and the study protocol was approved by
the local bioethics committee.
ELISA and Cytometric bead Array (CBA) of bone
remodeling molecules
Serum for bone remodeling molecules was obtained
from axSpA patients and controls and stored at − 20 °C.
RANKL, oncostatin M (OSM) (Elabscience Biotechnol-
ogy Co. Ltd., Wuhan, China), (Abbexa, Cambridge, UK),
M-CSF (R&D Systems, Minneapolis, MN, USA), OPG
(Ray-Biotech, Norcross GA, USA) and TGFβ (Thermo
Fisher Scientific Waltham, MA USA) were assessed by
ELISA. We used the RANKL kit which according to the
manufacturer has been developed from the human
Tumor Necrosis Factor ligand superfamily member 11
protein where the sequence of the immunogen rests
within the region Ile140~Asp317 and hence this kit is
designed to detect free soluble RANKL. The presented
M-CSF levels were assayed in a subsample of 13 patients
due to limited availability of patients’ material. Samples
were run in duplicates, according to the manufacturers
protocols, and results were obtained using an ELISA
reader (BioTek Instruments, Vinooski, VT).
Concentrations of IL-6, IL-17A, TNFα in the serum
were measured using the CBA system (BD Biosciences)
followed by flow cytometric analysis (FACS Canto). The
CBA beads were discriminated in FL-4 and FL-5 chan-
nels, while the concentration of specified cytokines was
determined by the intensity of FL-2 fluorescence, using
the respective standard reference curve and FCAP Array
software (BD Biosciences).
The detection levels were < 58 pg/ml for RANKL, 11
pg/ml for M-CSF and 1 pg/ml for OPG, 9,38 pg/ml for
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OSM, 156,3 pg/ml for TGFβ, 2,4 pg/ml for IL-6, 18,9 pg/
ml for IL-17A and 3,8 pg/ml for TNFα.
Cell culture of osteoclasts for cathepsin K and
RANK mRNA expression analysis
a. Differentiation of monocytes into osteoclasts
Peripheral blood from healthy donors was used to iso-
late monocytes, as described previously [11]. Briefly, per-
ipheral blood mononuclear cells (PBMC) were isolated by
the standard Ficoll/Isopaque (Pharmacia, Uppsala,
Sweden) density gradient centrifugation. Subsequent sep-
aration of monocytes form PBMC was performed with
JE-5.0 elutriation system, equipped with the Sanderson
separation chamber (Beckman, Palo Alto, CA, USA) [11].
Isolation purity was over 95% as tested by staining with
anti-CD14 mAb (BD Biosciences Pharmingen, San Diego,
CA) and flow cytometry analysis (FACSCanto flow cyt-
ometer, Becton Dickinson, San Jose, CA, USA). Mono-
cytes were seeded in 24-well plates at density of 2 × 105
cell/cm2 and cultured in RPMI 1640 medium (Corning)
supplemented with 10% serum (from randomly chosen
axial SpA patients, n = 11, or heathy controls, n = 10) and
50 μg/ml gentamycin for 14 days (with half of media
change every other day). Cells were cultured with
rhM-CSF (10 ng/ml) alone, or rhM-CSF and rhRANKL
(10 ng/ml) (both from Peprotech, London, UK), or with-
out addition of additional factors for the whole differenti-
ation period. After 14 days cells were harvested for RNA
isolation (Norgen, RNA purification kit).
b. Analysis of qRT-PCR
RNA (200 ng) from cultured cells was transcribed using
NG dART RT kit (EurX, Poland). qPCR for studied genes
was performed using SG qPCR Master Mix (EurX, Poland)
with QuantStudio 7 cycler (Thermo Scientific). The CT
values were normalised to housekeeping gene – GAPDH.
Results were analysed using standard 2-ΔΔCT method. Pri-
mer sequences used in this study: GAPDH_FW: AGAT
CATCAGCAATGCCTCCT, GAPDH_RV: TGGTCATGA
GTCCTTCCACG, Cathepsin K_FW: TTCCCGCAGTAA
TGACACCC, Cathepsin K_RV: GGAACCACACTGAC
CCTGAT, RANK_FW: TGGGACGGTGCTGTAACAAA,
RANK_RV: CCAAGTATTCATCCGGGCCA.
Tartrate-resistant acid phosphate (TRAP) activity
detection in monocyte-derived osteoclasts
For TRAP activity assay, monocytes were isolated and
cultured as described above for 20 days (with half of cell
culture medium refreshed every 3–4 days). Cells were
then fixed and stained for TRAP activity using commer-
cially available kit according to manufacturer’s protocol
(Sigma-Aldrich, Acid Phosphatase, Leukocyte [TRAP]
Kit). Large multinucleated cells (containing at least 3 nu-
clei) showing TRAP activity were considered as osteo-
clasts. For quantification of osteoclast differentiation
efficiency, cells fulfilling osteoclast criteria (TRAP activ-
ity + at least 3 nuclei) were counted (n = 12 representa-
tive microscope images for each condition) and the
percentage of osteoclasts was calculated.
X-ray of sacroiliac joints, cervical and lumbar spine
To assess structural damage radiographs of sacroiliac
joints were analyzed according to modified New York
(mNY) criteria; radiographs of the lateral cervical and
lumbar spine were collected to calculate the mSASSS
(modified Stoke Ankylosing Spondylitis Spinal Score).
Statistical analysis
Database management and analysis were performed
using SAS 9.2 (SAS Institute Inc. Cary, NC, USA) and
GraphPad PRISM (San Diego, CA) software packages.
The variables following a non-normal distribution are
presented as medians (25th–75th percentile) and those
that are normally distributed as means ± standard devia-
tions (SD). The non-normally distributed data were ana-
lyzed using nonparametric techniques (Wilcoxon’s test
for comparison of unpaired continuous data). The
means of normally distributed variables were compared
using Student’s t-test. The proportions were compared
using chi-square test. All Pvalues were two-tailed and
5% was considered as the threshold for significance.
Results
Demographic, clinical, inflammatory markers and x-ray data
Table 1 presents characteristics of patients and controls.
Mean age (years, SD) of studied patients was 32.9 (7.7), the
mean disease duration (years, p25-p75) was 7.5 (5–10) and
59.5% were male. A total of 66.7% of axSpA patients ful-
filled the mNYx-ray criteria for ankylosing spondylitis (AS).
Concentration of canonical osteoclastogenesis promoting
molecules in sera of axSpA patients and healthy donors
Concentrations of main osteoclastogenesis molecules,
i.e. RANKL and M-CSF were determined in sera from
axSpA patients and healthy donors. Sera levels of
RANKL in axSpA patients appeared significantly lower
(P = 0.016; median values: 8.5 vs. 272 pg/ml) and M-CSF
significantly higher (P = 0.0002; median values: 978.2 vs.
715.5 pg/ml) in comparison to healthy subjects (Fig. 1a, b).
OPG levels in axSpA did not differ from those in healthy
blood donors (P = 0.18) (Fig. 1c). Concentrations of these
factors were comparable upon division of the group of
axSpA patients into subgroups of non-radiographic SpA
and AS (data not shown).
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Cell culture of osteoclasts for mRNA expression of
Cathepsin K and RANK
To determine the effect of serum factors on osteoclast dif-
ferentiation, monocytes isolated from healthy donors were
cultured in the presence of serum from either axSpA pa-
tients or healthy blood donors for 14 days. Expectedly,
osteoclast differentiation was significantly higher when
cells were cultured in medium containing ostoclastogen-
esis stimulants – M-CSF and RANKL, as revealed by
qRT-PCR analysis for Cathepsin K – marker of mature os-
teoclasts. Intriguingly, Cathepsin K mRNA expression was
stimulated significantly stronger in presence of serum
from axSpA patients compared to the corresponding
healthy group (Fig. 2a). In order to elucidate the possible
cause of the observed difference we decided to measure
the level of RANK transcripts in these cells, that would in-
dicate the relative abundance of RANKL receptor at the
cell surface. Surprisingly, RANK mRNA expression was
significantly higher in all tested culture conditions in
which serum from axSpA patients was used compared to
the corresponding healthy serum groups. Importantly, in-
duction of RANK mRNA expression by axSpA serum was
independent of supplementation of cell culture medium
with such factors as M-CSF or M-CSF + RANKL, as the
observed stimulatory effect in all the “axSpA” conditions
was comparable (i.e. not statistically different) (Fig. 2b).
The above results were further corroborated using mono-
cytes isolated from another healthy blood donor and ran-
domly chosen sera from 6 healthy subjects and 7 axSpA
patients (data not shown). This data indicate that serum
from axSpA patients contains additional factors capable of
promoting RANK mRNA expression, independently of
serum RANKL and M-CSF levels.
Tartrate-resistant acid phosphate (TRAP) activity
detection in monocyte-derived osteoclasts
To confirm that isolated monocytes differentiate into oste-
oclasts in response to human sera, we subjected the
20 day in vitro monocyte cultures to TRAP activity detec-
tion (an well-established osteoclasts marker). We noticed
that monocytes cultured in presence of both axSpA or
healthy sera, but without supplementation with exogenous
factors, only sporadically differentiated into osteoclasts
– large, TRAP-positive cells with at least three nuclei
(Fig. 3a, b). On the other hand, addition of M-CSF
and RANKL to the cell culture medium greatly increased
osteoclast differentiation efficiency (Fig. 3c, d). Yet, al-
though cells with osteoclast phenotype were identified in
cultures using axSpA as well as healthy serum, osteoclasts
differentiation was more efficient in presence of axSpA
serum (Fig. 3e; 5.2 vs. 3.9%) and the derived cells were big-
ger and more mature (Fig. 3d), which seems to correspond
well to the qRT-PCR results presented above.
Concentration of non-canonical (i.e. RANKL-independent)
osteoclastogenesis factors in studied sera
In vitro osteoclast differentiation data indicates that axSpA
patients’ sera contains factors other than RANKL and
M-CSF that are capable of driving osteoclast generation
from monocytes. In search of possible candidates, sera levels
of so-called non-canonical osteoclastogenesis factors such
as IL-6, OSM, IL-17A, TNFα and TGFβ were determined.
Notably, levels of IL-6, OSM, IL-17A and TNFα were sig-
nificantly elevated in axSpA patients’ sera compared to sera
of healthy donors (Fig. 4a-d; median values: 8.515 vs. 5.710;
11.39 vs. 0.0; 23.39 vs. 17.37; 7.740 vs. 5.450 pg/ml respect-
ively). Concentrations of TGFβ did not differ between
Table 1 Characteristic of axSpA patients and healthy blood donor groups
axSpA patients Healthy subjects Pvalue
n, (%) 27 (56.25) 23 (43.75)
Age, mean ± SD years 32.9 (7.7) 35.1 (5.4) 0.31
Sex, % male 59.5 52.4 0.61
HLA B27 positive, % 91.7 N/A
Duration of symptoms, median (p25-p75) years 7.5 (5–10) N/A
IBP, % 88.5 N/A
CRP, median (p25-p75) mg/l 8.8 (2.4–12.9) 0.27 (0.18–0.54)a) < 0.0001
ESR, median (p25-p75) mm/h 22.5 (15.0–31.0) N/A
BASDAI (0–10 scale), median (p25-p75) 2.1 (0.8–4.4) N/A
ASDAS-CRP median (p25-p75) 2.1 (1.6–3.1) N/A
mNY x-ray criteria for AS (%) 66.7 N/A
mSASSS median (p25-p75) 3 (0–72) N/A
IBP inflammatory back pain, CRP C-reactive protein, ESR erythrocyte sedimentation rate, BASDAI Bath Ankylosing Spondylitis Disease Activity Index, ASDAS
Ankylosing Spondylitis Disease Activity Score, mNY modified New York, mSASSS modified Stokes Ankylosing Spondylitis Spinal Score
a)data obtained from randomly chosen 9 healthy blood donors
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studied groups (data not shown). IL-6, OSM, IL-17A and
TNFα have been shown to promote osteoclastogenesis in
both RANKL-dependent and RANKL-independent manner
[6, 9, 12, 13] and thus, elevated levels of these factors in sera
of axSpA patients may, at least partially, explain increased
osteoclastogenesis-promoting potential for of axSpA serum
as shown by in vitro differentiation experiments.
Discussion
In this study we analyzed serum bone remodeling mole-
cules in axSpA patients and healthy individuals along
with an in vitro model of differentiation of isolated,
healthy peripheral blood monocytes into active osteo-
clasts in various culture conditions. While a recent study
by Perpétuo et al. analyzed osteoclastogenic potential of
monocytes obtained from SpA patients, we evaluated for
the first time the effect of axSpA patients sera on mono-
cytes from healthy individuals, differentiated into osteo-
clast lineage [5].
We observed a significantly lower serum level of
RANKL and higher level of M-CSF in axSpA patients.
Importantly, lower RANKL concentration in sera of
axSpA patients were not due to increased level of
RANKL decoy receptor - OPG. Previous studies re-
ported higher or similar levels of RANKL in sera of SpA
patients compared do healthy donors [2–5]. The dis-
crepancies in RANKL level might be due to distinctive
patient’s characteristics, technical RANKL evaluation
and treatment modalities [2–5]. Therefore, a rigorous se-
lection of the SpA patients group (i.e. including only
axSpA patients with relatively recent disease onset that
were naïve to sDMARDs, bDMARDs and steroid treat-
ment, as such therapies are known to influence osteo-
clastogenesis) should be considered as substantial
advantage of the current study [14]. Another one was
the use of RANKL ELISA kit designed to detect free sol-
uble RANKL exclusively (see Methods).
In order to verify whether lower RANKL levels in sera
of axSpA patients were functionally meaningful, we ap-
plied an in vitro cell culture model. We used peripheral
blood monocytes isolated from healthy individuals and
subjected them to differentiation towards osteoclasts using
sera from axSpA patients and healthy blood donors (with
osteoclastogenic inducers such as M-CSF or/and RANKL
or without). We found that under control conditions (cul-
ture medium with serum alone) or in the presence of
M-CSF, osteoclast activity reflected by expression of ca-
thepsin K mRNA, was comparable for treatments with
serum from axSpA patients and healthy donors. However,
in the presence of exogenous RANKL (but not M-CSF),
which represents key osteogenic factor, the osteoclasts ac-
tivity was higher in cultures treated with sera from axSpA
group. It seems that factors present in sera from controls
or axSpA patients induce comparable osteoclasts gener-
ation despite of relative low RANKL levels in axSpA
group. However, our data point to other factors in patient
serum, which predispose monocytes for boosted osteo-
clastogenesis in the presence of high RANKL levels, as
mimicked in our settings by stimulation with rhRANKL.
Fig. 1 Determination of RANKL, M-CSF and OPG serum levels.
Concentrations of RANKL, M-CSF and OPG in sera of axSpA patients
(n = 27) and healthy individuals (n = 23). RANKL was found
significantly lower (P = 0.016; median values: 8.5 vs. 272 pg/ml) (a)
and M-CSF significantly higher (P = 0.0002; median values: 978.2 vs.
715.5 pg/ml) (b) in axSpA patients’ sera. OPG levels were comparable
(P = 0.18) (c). Data presentation: Median + interquartile ranges.
Statistics: Wilcoxon’s test for non-normally distributed data
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Fig. 2 Cathepsin K and RANK gene expression analysis. qPCR analysis of Cathepsin K mRNA (a) and RANK mRNA (b) expression in monocytes
differentiated to osteoclasts for 14 days in presence of serum from axSpA patients (n = 11) and healthy donors (n = 10). Addition of the exogenous
rhRANKL boosted, independently of M-CSF, osteoclastogenesis which was significantly higher in cultures with axSpA sera (in comparison the control
sera), as assessed by Cathepsin K mRNA expression (a) (*** P = 0.0004, mean values: 3.752 vs. 5.957). Supplementation of the culture media with rhM-
CSF and/or rhRANKL did not influenced RANK mRNA expression, which was dependent only of axSpA patients sera admixture. axSpA or Healthy –
sera obtained from axSpA patients or control blood donors (b). * (P = 0.0491, mean values: 1.096 vs. 2.028; ** P = 0.0018, mean values:
1.258 vs. 2.545; ** P = 0.0017, mean values: 1.081 vs. 2.378 respectively). Data presentation: box = median with interquartile ranges, whiskers
– min/max value. Statistics: One-way ANOVA with Tukey’s correction for multiple testing
Fig. 3 TRAP staining of monocyte-derived osteoclasts. Monocytes were differentiated to osteoclasts for 20 days in presence of serum from axSpA
patients and healthy donors as described in “materials & methods”. a-d Cells were fixed and stained to detect TRAP activity. TRAP-positive (violet-
labeled) cells with at least three nuclei were considered osteoclasts (blue arrows). e Quantification of osteoclast differentiation efficiency. Graph
represent the mean + SD quantified form n = 12 representative micrographs for each condition. (*P = 0.0344; mean values: 3.9 vs. 5.2%). Statistics:
One-way ANOVA with Tukey’s correction for multiple testing
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Considering lower serum RANKL in axSpA group we
argue that above results may support the hypothesis that
regardless of endogenous level of RANKL in axSpA, the
patient sera activate healthy monocytes to accelerate
osteoclast differentiation, while under exposure to
RANKL. The possible mechanism is that those serum
factors induce expression of RANK on monocytes as
RANKL-RANK interaction is considered critical for effi-
cient transition from monocytes to osteoclasts. We
tested such a possibility and found that serum from
axSpA patients – in comparison to serum from healthy
donors – significantly increased the expression of
RANK mRNA in monocytes. However, in this case, it
was independent on exogenous M-CSF and/or RANKL.
Such a result may explain why rhRANKL increased Ca-
thepsin K mRNA expression in monocyte-derived osteo-
clasts in axSpA patient group. It is likely that soluble
factors present in axSpA sera sensitize monocytes to
osteoclastogenic response, which is in accordance with
former observations (without explanation of its bio-
logical significance) of high RANK protein expression
on SpA monocytes [5]. Such a preconditioning mechan-
ism could possibly be utilised by osteoclast precursors,
which, subjected to high RANKL levels within local tis-
sue microenvironment, could efficiently and rapidly dif-
ferentiate into mature osteoclasts.
In search for factors that could drive such a
sensitization of osteoclasts precursors to RANKL we
assessed the sera levels of several RANKL-independent
osteoclastogenesis factors in axSpA patients and healthy
donor groups. Although not formally proven in our
work, we might assume that significantly elevated levels
of IL-6, OSM, IL-17A and TNFα in axSpA sera were re-
sponsible for enhanced osteoclastogenesis, as these mole-
cules have been already identified to be involved in
non-canonical pathways of osteoclastogenesis [6, 9, 12].
TNFα, for instance, is capable of inducing ostoclastogen-
esis in both RANKL-independent and RANKL-synergistic
way [15]. Interestingly, as shown by another group, TNFα
alone failed to induce osteoclast differentiation from mac-
rophages [16]. On the other hand, in combination with
low concentrations of RANKL (100 times lower than nor-
mally required for osteoclast differentiation) TNFα po-
tently stimulated osteoclastogenesis [16]. Given lower
concentrations of RANKL and higher levels of TNFα in
serum of axSpA patients observed in our study, similar
bone destruction mechanisms may operate in SpA path-
ology. Well established is also RANKL-independent osteo-
clastogenesis potential of IL-6. Among others, IL-6 (in
combination with M-CSF) was shown to potently stimu-
late osteoclast differentiation of human monocytes [17].
IL-17A, on the contrary, was clearly demonstrated to en-
hance osteoclastogenesis by inducing expression of RANK
on human CD14-positive osteoclast precursors [18].
OSM, on the other hand, was linked to increased osteo-
clastogenesis when acting through OSM receptor [19].
Fig. 4 Serum levels of non-canonical osteoclastogenesis-promoting factors. Concentrations of IL-6, OSM and IL-17A and TNFα (a-d) in sera of
axSpA patients (n = 27) and healthy individuals (n = 23). Levels of examined cytokines were found significantly higher in axSpA patients’ sera
(median values: 8.515 vs. 5.710; 11.39 vs. 0.0; 23.39 vs. 17.37; 7.740 vs. 5.450 pg/ml respectively). Data presentation: Median with interquartile
ranges. Statistics: Wilcoxon’s test for non-normally distributed data
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Essentially, some of the molecules mentioned above
were shown to act synergistically in promoting bone
destruction. For instance OSM together in combin-
ation with TNFα was demonstrated to stimulate
RANK/RANKL expression in a model of inflamma-
tory arthritis especially at the site of bone erosion
[20]. Considering pro-osteoclastogenic activity of IL-6,
OSM, IL-17A and TNFα, it seems reasonable to
speculate that these factors (whether acting separately
or simultaneously) may function as osteoclast precur-
sors sensitizers in the course of SpA, regardless of in-
nate monocyte functional properties in these patients.
Furthermore, intrinsic monocyte properties accompan-
ied by dysregulated immune response may constitute an
important driver of osteoclastogenesis in SpA. As de-
scribed recently, exaggerated proinflammatory response
may be associated with defects in autophagy in non-clas-
sical CD14−CD16++ monocytes that results in increased
inflammasome activity and uncontrolled inflammatory
mediators production in AS [21]. Thus, CD14−CD16++
non-classical monocytes, as one of the cellular sources
of proinflammatory cytokines, would be responsible for
induction of alternative osteoclastogenesis pathways
and/or cytokine-producing lymphocytes that could in-
duce osteoclast differentiation of classical CD14++CD16−
monocytes – the main source of osteoclasts in human
[22]. Additionally, an upregulation of proteins involved
in inflammation and the ubiquitin proteasome pathway
was shown in AS monocytes [23]. Such an intrinsic
property of AS monocytes could promote chronic in-
flammation (in line with our results showing increased
levels of proinflammatory cytokines in SpA patient’s
sera) that might result in (observed in our experiments)
increased RANK expression and directly lead to osteo-
clastogenesis induction. In an arthritis mouse model, ele-
vated RANK signalling was demonstrated to contribute to
higher RANKL responsiveness and osteoclast differenti-
ation of inflammatory non-classical monocytes [24]. In
mice therefore, non-classical monocytes were shown to be
pivotal cells in tissue damage in arthritis. Similar mechan-
ism may in part play a role in human, however caution
must be taken in direct transferring results obtained with
mouse monocytes to human setup as monocyte popula-
tions in different species were shown not to be functionally
equivalent [25]. Summaraising, the growing body of evi-
dence suggests that in such a disease as SpA, augmented
osteoclastogenesis may be secondary to dysregulated proin-
flammatory response.
Our outcomes should be seen in the context of their
limitations. These results should be viewed as hypothesis
generating. We assessed the serum levels of cytokines,
and thus we do not know whether the same associations
would be true for the synovial fluid, synovial and enthe-
sial tissues and for bone tissue. What is more, all such
analyses are potentially burdened with multiple-testing
bias. In our comparisons of molecule levels in patients
and healthy subjects, the adjustment for multiple testing,
with an exception for RANKL (P = 0.07 from P = 0.016)
did not alter the inferences. It seems likely that the levels
of certain molecules, eg. RANKL may be higher in local
microenvironment than in the serum [26]. This points
out that despite of systemic low soluble RANKL concen-
tration in axSpA patients and therefore disturbed global
osteoclastogenesis, it is possible that locally produced
RANKL may simultaneously induce paradoxically highly
active osteoclasts from their precursors. This concept
would, at least in part, explain why in axSpA patients
osteogenesis is accompanied by bone loss.
Conclusions
Our study indicates that sera from axSpA patients contain
factors that promote osteoclastogenesis by up-regulating
RANK mRNA level in monocytes and, by that, boosting
their responsiveness to RANKL. Such mechanism would
explain paradoxically higher osteoclast activity in axSpA
patients compared to healthy people despite low systemic
RANKL levels. As indicated by our data, these factors
could include IL-6, OSM, IL-17A and TNFα, but the as-
sessment of their functional relationship to axSpA patho-
physiology requires further studies.
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